Meeting
2019 Genitourinary Cancers Symposium
TROPHY-u-01: A phase II open-label study of sacituzumab govitecan (IMMU-132) in patients with advanced urothelial cancer after progression on platinum-based chemotherapy and/or anti-PD-1/PD-L1 checkpoint inhibitor therapy.
Authors
Scott T. Tagawa
Weill Cornell Medical Center, New York, NY
Scott T. Tagawa , Daniel Peter Petrylak , Petros Grivas , Neeraj Agarwal , Cora N. Sternberg , Peggy Siemon-Hryczyk , Trishna Goswam , Yohann Loriot
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Trials in Progress Poster Session
Session Title
Trials in Progress Poster Session B: Prostate Cancer; Urothelial Carcinoma; Penile, Urethral, Testicular, and Adrenal Cancers
Track
Urothelial Carcinoma,Prostate Cancer,Penile, Urethral, Testicular, and Adrenal Cancers
Sub Track
Urothelial Carcinoma
Clinical Trial Registration Number
NCT03547973
Citation
J Clin Oncol 37, 2019 (suppl 7S; abstr TPS495)
DOI
10.1200/JCO.2019.37.7_suppl.TPS495
Abstract #
TPS495
Poster Bd #
N5
Abstract Disclosures
Similar Posters
Poster
2019 ASCO Annual Meeting
TROPHY-U-01: A phase II open-label study of sacituzumab govitecan (IMMU-132) in patients with advanced urothelial cancer after progression on platinum-based chemotherapy and/or anti-PD-1/PD-L1 checkpoint inhibitor therapy.
First Author: Scott T. Tagawa
Poster
2023 ASCO Genitourinary Cancers Symposium
Updated outcomes in TROPHY-U-01 cohort 1, a phase 2 study of sacituzumab govitecan (SG) in patients (pts) with metastatic urothelial cancer (mUC) that progressed after platinum (PT)-based chemotherapy and a checkpoint inhibitor (CPI).
First Author: Scott T. Tagawa
Poster
2021 Genitourinary Cancers Symposium
Phase II open-label study of S-588410 as maintenance monotherapy after first-line platinum-containing chemotherapy in patients with advanced or metastatic urothelial carcinoma.
First Author: Syed A. Hussain
Poster
2020 Genitourinary Cancers Symposium
A phase II trial of regorafenib for advanced urothelial cancer (aUC) following prior chemotherapy.
First Author: Gurudatta Naik